Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Purity: ≥98%
PR-104, a novel, potent, non-toxic, small-molecule, hypoxia-activated, 3,5-dinitrobenzamide nitrogen mustard, is a drug from the class of hypoxia-activated prodrugs (HAPs), which is being researched as a potential anti-cancer therapeutic agent. It is a phosphate ester “pre-prodrug” that is rapidly converted to the HAP PR-104A in the body. PR-104A is in turn metabolised to reactive nitrogen mustard DNA crosslinking agents in hypoxic tissues such as found in solid tumours. Following initial clinical studies, it was discovered that PR-104A is also activated by the enzyme AKR1C3, independently of hypoxia. Hypoxia in the bone marrow of patients with leukaemia, and high activity of AKR1C3 in some leukaemia subtypes has led to interest in clinical trials of PR-104 in relapsed refractory acute leukaemias
ln Vitro |
In anoxic rather than aerobic settings, PR-104 (80 μM; 1 h; SiHa cells) exhibits a higher inhibitory impact on radiation-induced DNA single-strand breaks. Ser139 on histone H2AX (gH2AX) is phosphorylated by PR-104 (100 μM; 1 hour; SiHa cells). Following radiation, PR-104 (0.266 mmol/kg; 18 h; SiHa cells) shown efficacy against hypoxic cells. Different cell lines have different potencies of PR-104; H460 cells have the lowest IC50 (0.51 μmol/L) while PC3 prostate cells have the highest (7.3 μmol/L) [1].
|
---|---|
ln Vivo |
The plasma area under the curve is increased by PR-104 (0.56 mmol/kg; iv or ip; 0~2 hours). PR-104 exhibits antitumor activity (0.23 mmol/kg; intraperitoneal; 100 days) [1].
|
Animal Protocol |
Animal/Disease Models: CD-1nu/nu mouse
Doses: 0.56 mmol/kg (pharmacokinetic/PK/PK analysis) Route of Administration: intravenous (iv) (iv)injection or intraperitoneal (ip) injection Experimental Results: plasma area under the curve. Animal/Disease Models: CD1-Foxn1nu mouse Doses: 0.23 mmol/kg Route of Administration: intraperitoneal (ip) injection Experimental Results:demonstrated anti-tumor activity. |
References |
[1]. Patterson AV, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res. 2007;13(13):3922-3932.
|
Molecular Formula |
C14H20N4O12PSBR
|
---|---|
Molecular Weight |
579.271
|
CAS # |
851627-62-8
|
Related CAS # |
PR-104 sodium;851627-80-0
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
CS(=O)(OCCN(CCBr)C1=C(C(NCCOP(O)(O)=O)=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O)=O
|
InChi Key |
GZSOKPMDWVRVMG-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C14H20BrN4O12PS/c1-33(28,29)31-7-5-17(4-2-15)13-11(14(20)16-3-6-30-32(25,26)27)8-10(18(21)22)9-12(13)19(23)24/h8-9H,2-7H2,1H3,(H,16,20)(H2,25,26,27)
|
Chemical Name |
2-((2-bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate
|
Synonyms |
PR 104; PR-104; PR104.
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~172.63 mM)
H2O : ~31.25 mg/mL (~53.95 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (8.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (8.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7263 mL | 8.6316 mL | 17.2631 mL | |
5 mM | 0.3453 mL | 1.7263 mL | 3.4526 mL | |
10 mM | 0.1726 mL | 0.8632 mL | 1.7263 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.